Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation (NASDAQ:SRRK) is one of the best-performing stocks on Thursday.

Scholar Rock jumped by 16.6 percent on Wednesday to close at $36.32 apiece as investor sentiment was bolstered by the positive results from the second phase of its weight loss drug trial.

In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab’s combination with tirzepatide, was generally well tolerated, leading to higher quality weight loss as compared with taking tirzepatide alone.

According to Scholar Rock Holding Corporation (NASDAQ:SRRK), apitegromab therapy in combination with tirzepatide resulted in the preservation of 4.2 pounds of lean mass compared with tirzepatide alone.

“While this is an exciting development for our platform, we remain focused on preparing for the launch of apitegromab, and following its potential approval in SMA, we look forward to studying it in a range of neuromuscular diseases with high unmet need,” said Scholar Rock Holding Corporation (NASDAQ:SRRK) President and CEO Akshay Vaishnaw, adding that he was looking forward to exploring its potential in various rare, severe debilitating neuromuscular disorders.

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

A scientist holding a flask of liquid in a laboratory, highlighting the research and discoveries of new treatments.

“We remain on track to file an IND application for SRK-439 in the second half of this year to support the first in human study,” he said.

While we acknowledge the potential of SRRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.